Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ISRIB and Piracetam — mechanism, dosing, side effects, legal status, and pricing.
ISRIB is a non-peptide small-molecule eIF2B activator (bis-chlorophenoxyacetamide-cyclohexane class) that antagonizes the integrated stress response (ISR) by stabilizing the eIF2B guanine-nucleotide exchange factor complex. It is not an approved drug and has no completed human clinical trials or validated human safety or efficacy data. Chemically distinct eIF2B-activator analogs (DNL343, ABBV-CLS-7262) have reached human trials, but DNL343 missed primary endpoints in a Phase 2/3 ALS trial (January 2025). ISRIB is sold by reagent suppliers for research use only.
Piracetam is a non-peptide pyrrolidinone-derivative racetam, the prototypical member of the nootropic racetam class. It is approved in the EU/UK exclusively for adult cortical myoclonus as adjunctive therapy (marketed as Nootropil), but has NO FDA approval in any form in the United States. The FDA has rejected its New Dietary Ingredient notification and issued warning letters to US vendors marketing it as a supplement. Piracetam itself is not WADA-prohibited, though its derivative phenylpiracetam is a banned stimulant.
ISRIB
Piracetam
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ISRIB
Piracetam
No pricing data yet.
Check Piracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
ISRIB
1
COAs
99.8%
Avg purity
1
Labs
Piracetam
1
COAs
99.8%
Avg purity
1
Labs
No completed or published human clinical trials of ISRIB itself exist; it has no validated human pharmacokinetic, safety, or efficacy data. In mice, systemic ISRIB enhanced spatial and fear-associated long-term memory in healthy animals, reversed hippocampus-dependent spatial-learning and working-memory deficits weeks after traumatic brain injury, and reset elevated ISR activity in aged (18–24 month) mice, reversing age-related spatial-memory decline with a brief 3-day dosing course. In prion-disease transgenic mice, ISRIB partially restored protein synthesis and prevented neurodegeneration without the pancreatic exocrine toxicity seen with PERK-inhibitor approaches. In vitro and in a patient-derived xenograft mouse model, ISRIB combined with imatinib attenuated RAS/RAF/MAPK and STAT5 signaling and eliminated therapy-resistant chronic myeloid leukemia cells.
Key references
Piracetam is an approved prescription drug in the EU/UK for adult cortical myoclonus (adjunctive therapy) and has been studied off-label in multiple placebo-controlled human trials for age-related cognitive decline, post-stroke aphasia, post-ECT cognitive deficit, and post-CABG cognitive decline, with mixed results. A Cochrane systematic review (2001) concluded that available evidence does not support piracetam's use for dementia or cognitive impairment beyond a global-impression measure. In rodent models, piracetam reduced focal ischemia infarct volume by ~35.8%, improved neurological/locomotor outcomes and survival, attenuated oxidative stress and excitatory amino acid release in oxygen-glucose deprivation, and showed anticonvulsant and neuroprotective effects in PTZ-induced epilepsy.
Key references
ISRIB and Piracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs